PFIZER

REPORT ON EXPORTING ANIMAL TESTING

This Proposal is submitted by Julia Randall.

RESOLVED, that the Board report to shareholders on the rationale for increasingly exporting the Company's animal experimentation to countries which have either nonexistent or substandard animal welfare regulations and little or no enforcement. Further, the shareholders request that the report include information on the extent to which Pfizer requires adherence to U.S. animal welfare standards at facilities in foreign countries.

Supporting Statement:

Pfizer has publicly committed to the "3Rs" of animal research:

- Refinement of the use of research animals to use less painful or the least invasive procedures whenever possible.
- Reduction of the numbers of animals used in each study to the absolute minimum necessary.
- Replacement of animal experiments with non-animal experiments.¹

Furthermore, the Company declares that "[e]very proposed use of animals in our research will be thoroughly evaluated and the health and well being of all laboratory animals under our care will be attended to meticulously." However, some of the countries to which the Company is relocating its animal research are known for having no or poor animal welfare standards and negligible oversight.

In October 2005, Pfizer announced the opening of a new Research & Development Center in Shanghai, China, with Pfizer's Chief Medical Officer stating that "Pfizer's planned

¹ http://www.pfizer.com/responsibility/laboratory_animal_care.jsp
investment into this R&D center will near US$25 million over the next 5 years.\textsuperscript{2} Company sources stated that "research and development in China is an indispensable part of the company's global R&D program\textsuperscript{3}" and that "[t]he Pfizer investment in this centre demonstrates ... our commitment to broaden the scope of our operations here in China."\textsuperscript{4}

The November 13, 2006, issue of\emph{Forbes} magazine reported on Pfizer's research in China, noting that the rationale for shifting animal testing to China is that "scientists are cheap, lab animals plentiful and pesky protesters held at bay" and quoting a pharmaceutical industry executive who "admits that Chinese testing companies lack quality control and high standards on treatment."\textsuperscript{5}

Our Company now conducts a significant proportion of its research in foreign laboratories. Purposely relocating research to countries with lower animal costs, easy animal availability, and lower welfare standards is in direct conflict with Pfizer's stated commitment to the 3Rs.

As recent media reports of safety scandals and product recalls have made abundantly clear, standards for products exported from China to the U.S. are lacking. Shareholders deserve to understand why animal testing is being moved to foreign countries, such as China. Moreover, our Company should report on the steps that are being taken to ensure that animal testing conducted in other countries is held to at least the same animal welfare standards as testing conducted here.

We urge shareholders to support this resolution.

\begin{itemize}
\item [\textsuperscript{3}] "Pfizer Inaugurates R&D Center in Shanghai", People's Daily (Nov. 1, 2005)
\item [\textsuperscript{4}] "Pfizer's Strategic Presence in China", China Daily, p.3 (Nov. 1, 2005)
\item [\textsuperscript{5}] "Comparative Advantage", Forbes, p. 76 Vol. 178 No. 10 (Nov. 13, 2006)
\end{itemize}